Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma
Frontiers in Endocrinology · 08.05.2026 · 17
DOI: 10.3389/fendo.2026.1827644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 08.05.2026. Verfasst von Mahir Hasan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Touro University College of Osteopathic Medicine, Las Vegas, NV, United States. Hauptthemen laut MEDLINE: Ipilimumab, Melanoma, Hypopituitarism, Nivolumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Combination immunotherapy with ipilimumab and nivolumab has improved long-term progression-free and overall survival in patients with metastatic melanoma. Unfortunately, a high percentage of patients develop immune-related side effects, including endocrinopathy. The incidence and timing of hypopituitarism remains poorly characterized.
Methods
We routinely performed laboratory screening for hypopituitarism and hypothyroidism every 3–4 weeks on each treatment visit for patients receiving first-line ipilimumab plus nivolumab therapy for metastatic melanoma. A retrospective analysis of patient treatment records was performed to determine the incidence and timing of biochemical evidence for endocrinopathy.
Results
Records from 59 sequential patients treated with first-line combination immunotherapy were reviewed. Endocrinopathy was detected in 44.1%, including 18.7% with hypopituitarism and 25.4% with primary hypothyroidism. The median time to onset of was 72.5 ± 107.3 and 58 ± 48.7 days, respectively. Only one patient developed delayed onset of hypothyroidism, 3 months after elective treatment discontinuation. Development of endocrinopathy trended with improved clinical outcomes. All patients underwent prompt endocrine replacement therapy, and only one patient required hospitalization for symptomatic hypopituitarism.
Conclusions
Both the standard and alternate regimens of ipilimumab plus nivolumab treatment resulted in biochemical evidence for endocrinopathy in 54.6% and 38.9% of treated patients, respectively. Endocrinopathy always presented during or shortly following active treatment. Delayed onset of endocrinopathy was uncommon. Prompt replacement therapy allowed continuation of immune checkpoint inhibitors and minimized the risk for hospitalizations. Due to the high incidence of hypopituitarism, routine monitoring of both pituitary and thyroid and function of patients is strongly recommended receiving combination immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Touro University College of Osteopathic Medicine, Las Vegas, NV, United States.
- Department of Internal Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV, United States.
- Nevada Oncology Specialists, Las Vegas, NV, United States.
- Palm Medical Group, Las Vegas, NV, United States.
Zitieren
APA
Hasan, M., Samlowski, W., & Nakhle, S. (2026). Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1827644
Vancouver
Hasan M, Samlowski W, Nakhle S. Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1827644
BibTeX
@article{Hasan2026,
author = {Hasan, Mahir and Samlowski, Wolfram and Nakhle, Samer},
title = {Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.1827644}
}
EUVIMED